US4462985A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Delivery of biologically active components of heterologous species interferon isolates
Assignee: University of Illinois Foundation
•
Filing: 1982-09-07
•
Granted: 1984-07-31
•
Expires: 2002-09-07
Abstract
Abstract Interferon glycoprotein isolates of heterologous species origin are subjected to treatment in a digestive environment and non-species-specific biologically active fractions thereof are administered, preferably through digestive tract tissue, to the circulatory system of mammals, including humans, to secure antiviral, antiproliferative (e.g., antineoplastic) and immunomodulatory (e.g., immunopotentiating) effects ordinarily associated only with parenteral administration of homologous species interferon.
Inventors
- 👤 Joseph M. Cummins, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 19:34
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/565; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/811
Claims Analysis
Total Claims: 20
Claim 1
Independent Claim
99 words
In the method for enhancing the competence of a non-human mammal's response to viral and neoplastic disease states wherein exogenous interferon is provided to the circulatory system of a mammal in need of such enhancement, the improvement comprising: administering to the alimentary canal of the recipient mammal an effective amount of interferon isolated from cells of heterologous mammalian species origin, whereby said interferon is subjected to a digestive environment in the recipient mammal's digestive tract and the non-species-specific antiviral or antineoplastic fraction of said interferon is absorbed through digestive tract tissue and transported to the recipient mammal's circulatory system.
Claim 2
Dependent Claim
99 words
In the method for enhancing the competence of a non-human mammal's response to viral and neoplastic disease states wherein exogenous interferon is provided to the circulatory system of a mammal in need of such enhancement, the improvement comprising: administering to the alimentary canal of the recipient mammal an effective amount of interferon isolated from cells of heterologous mammalian species origin, whereby said interferon is subjected to a digestive environment in the recipient mammal's digestive tract and the non-species-specific antiviral or antineoplastic fraction of said interferon is absorbed through digestive tract tissue and transported to the recipient mammal's circulatory system.
Claim 3
Dependent Claim
42 words
The improvement of claim 1 wherein the quantity of interferon administered to the alimentary canal comprises, in unit dosage form, from about 10 to about 1,000 units per kg of body weight in combination with a pharmaceutically acceptable diluent, adjuvant or carrier.
Claim 4
Dependent Claim
29 words
The improvement of claim 1 wherein said interferon isolated from cells of heterologous species origin is isolated from cells of human, feline, bovine, equine, laprine or procine species origin.
Claim 5
Dependent Claim
19 words
The improvement of claim 1 wherein the recipient mammal is of the feline, bovine, equine, laprine or procine species.
Claim 6
Dependent Claim
46 words
The improvement of claim 1 wherein said interferon isolated from cells of heterologous species origin is isolated from cells of bovine species origin, the recipient animal is of the feline species and the response to be enhanced is a response to a feline leukemia disease state.
Claim 7
Dependent Claim
92 words
In the method for enhancing the competence of a human's response to a viral disease state wherein exogenous interferon is provided to the circulatory system of a human in need of such enhancement, the improvement comprising: administering to the alimentary canal of the recipient an effective amount of interferon isolated from cells of heterologous mammalian species origin, whereby said interferon is subjected to a digestive environment in the recipient's digestive tract and the non-species-specific antiviral fraction of said interferon is absorbed through digestive tract tissue and transported to the recipient's circulatory system.
Claim 8
Dependent Claim
92 words
In the method for enhancing the competence of a human's response to a viral disease state wherein exogenous interferon is provided to the circulatory system of a human in need of such enhancement, the improvement comprising: administering to the alimentary canal of the recipient an effective amount of interferon isolated from cells of heterologous mammalian species origin, whereby said interferon is subjected to a digestive environment in the recipient's digestive tract and the non-species-specific antiviral fraction of said interferon is absorbed through digestive tract tissue and transported to the recipient's circulatory system.
Claim 9
Dependent Claim
42 words
The improvement of claim 6 wherein the quantity of interferon administered to the alimentary canal comprises, in unit dosage form, from about 10 to about 1,000 units per kg of body weight in combination with a pharmaceutically acceptable diluent, adjuvant or carrier.
Claim 10
Dependent Claim
28 words
The improvement of claim 6 wherein said interferon isolated from cells of heterologous species origin is isolated from cells of feline, bovine, equine, laprine or procine species origin.
Claim 11
Dependent Claim
23 words
The improvement of claim 6 wherein said interferon isolated from cells of heterologous species origin is isolated from cells of bovine species origin.
Claim 12
Dependent Claim
11 words
The improvement of claim 9 wherein said interferon is fibroblast interferon.
Claim 13
Dependent Claim
20 words
The improvement of claim 9 wherein the response to be enhanced is a response to a benign papilloma disease state.
Claim 14
Dependent Claim
92 words
In the method for enhancing the competence of a human's response to a neoplastic disease state wherein exogenous interferon is provided to the circulatory system of a human in need of such enhancement, the improvement comprising: administering to the alimentary canal of the recipient an effective amount of interferon isolated from cells of heterologous mammalian species origin, whereby said interferon is subjected to a digestive environment in the recipient's digestive tract and the non-species-specific antineoplastic fraction of said interferon is absorbed through digestive tract tissue and transported to the recipient's circulatory system.
Claim 15
Dependent Claim
92 words
In the method for enhancing the competence of a human's response to a neoplastic disease state wherein exogenous interferon is provided to the circulatory system of a human in need of such enhancement, the improvement comprising: administering to the alimentary canal of the recipient an effective amount of interferon isolated from cells of heterologous mammalian species origin, whereby said interferon is subjected to a digestive environment in the recipient's digestive tract and the non-species-specific antineoplastic fraction of said interferon is absorbed through digestive tract tissue and transported to the recipient's circulatory system.
Claim 16
Dependent Claim
42 words
The improvement of claim 12 wherein the quantity of interferon administered to the alimentary canal comprises, in unit dosage form, from about 10 to about 1,000 units per kg of body weight in combination with a pharmaceutically acceptable diluent, adjuvant or carrier.
Claim 17
Dependent Claim
28 words
The improvement of claim 12 wherein said interferon isolated from cells of heterologous species origin is isolated from cells of feline, bovine, equine, laprine or procine species origin.
Claim 18
Dependent Claim
23 words
The improvement of claim 12 wherein said interferon isolated from cells of heterologous species origin is isolated from cells of bovine species origin.
Claim 19
Dependent Claim
11 words
The improvement of claim 15 wherein said interferon is fibroblast interferon.
Claim 20
Dependent Claim
20 words
The improvement of claim 15 wherein the response to be enhanced is a response to a malignant melanoma disease state.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-31 | 1988-01-30 | 1988-07-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-31 | 1992-01-30 | 1992-07-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-31 | 1996-01-30 | 1996-07-31 | $7700.00 | Window Closed / Lapsed |